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	Retroperitoneal hemorrhage is a rare bleeding complication of PCI which is independently associated with an increased risk of mortality and adverse events. There is currently no data from national cohorts describing how retroperitoneal hemorrhages have evolved over time nationally and what has driven these changes.
What the Study Adds:
	Our analysis of a national PCI cohort has demonstrated that the incidence of retroperitoneal hemorrhage has decreased over time in a country that has predominantly transitioned to transradial access for PCI.
	95% of retroperitoneal hemorrhage occurred in patients who underwent PCI through the femoral approach (which independently increased the odds of sustaining a retroperitoneal hemorrhage over 20 fold). 




Background: RH is a rare bleeding complication of PCI, which can result both as a consequence of femoral access or can occur spontaneously. This study aims to evaluate temporal changes in retroperitoneal hemorrhage (RH), its predictors and clinical outcomes in a national cohort of patients undergoing percutaneous coronary intervention (PCI) in the United Kingdom (UK). 
Methods and Results: We analyzed RH events in patients who underwent PCI between 2007-2014.  Multiple logistic regression models were used to identify factors associated with RH and to quantify the association between RH and 30-day mortality and major adverse cardiovascular events (MACE). 511,106 participants were included and 291 in-hospital RH events were recorded (0.06%).  Overall, rates of RH declined from 0.09% to 0.03% between 2007 and 2014. The strongest independent predictors of RH events were femoral access (OR=19.66; 95% CI: 11.22, 34.43), glycoprotein IIb/IIIa inhibitor (OR=2.63; 95%CI: 1.99, 3.47) and warfarin use (OR=2.53; 95% CI: 1.07, 5.99). RH was associated with a significant increase in 30-day mortality (OR=3.59; 95% CI: 2.19, 5.90) and in-hospital MACE (OR=5.76; 95% CI: 3.71, 8.95). A legacy effect was not observed; patients with RH who survived 30-days did not have higher 1 year mortality compared to those without this complication (HR=0.97; 95% CI: 0.49, 1.91).
Conclusions: Our results suggest that RH is a rare event that is declining in the United Kingdom, related to transition to transradial access site utilization but remains a clinically important event associated with increased 30-day mortality but no long term legacy effect.
  




Retroperitoneal hemorrhage is a rare bleeding complication of PCI, which can result both as a consequence of femoral access1 or can occur spontaneously,2,3 and has been shown to be independently associated with an increased risk of mortality and adverse events.4 Previous studies have reported varying retroperitoneal hemorrhage rates after PCI depending on the population and clinical setting studied, the access site utilized and the way that the events were captured, with previous literature derived mainly from North American database cohorts4,5 or small single center reports1,6-8 reporting rates ranging from 0.025 to 0.9%.4-6,8,9 
Femoral access is an important determinant of retroperitoneal hemorrhage and previous studies have only evaluated factors that are associated with bleeding events in cohorts where only femoral access was used in PCI.  Factors identified included female sex, sheath superior to inferior epigastric artery, glycoprotein IIb/IIIa inhibitor use, low body weight, low body surface area, history of COPD and sheath size >8 Fr.5,7,10  
In the UK there has been a change in access site practice from femoral to radial access,11-13 that has reduced access site related bleeding complications and has been estimated to be associated with over 450 lives saved in a 8-year study period.11 There is currently no data from national cohorts describing and how retroperitoneal hemorrhages have evolved over time in relation to changes in access site practices nationally. Furthermore, retroperitoneal bleeds may also occur spontaneously in patients in whom the access site utilized was radial, and the incidence, predictors and the outcomes of such spontaneous events has not been previously studied. We therefore report the temporal changes in retroperitoneal hemorrhage, its predictors and clinical outcomes in an unselected cohort of patients undergoing PCI in England and Wales at a time in which national access site practice had changed, through analysis of the British Cardiovascular Intervention Society Database.

Methods
The data cannot be made available for other researchers for purposes of reproducing the results or replicating the procedure, due to the absence of permission for data sharing from the National Institute of Cardiovascular Outcomes Research (NICOR) but the analytical methodology for the study is shared. Detailed description of the data source, data collection and statistical analysis are described in Data Supplements 1.  Ethical approval was not required for analysis of anonymized records as a part of a national audit.
The British Cardiovascular Intervention Society (BCIS) collects information in a database on 99% of all PCI procedures performed in National Health Service Hospitals in England and Wales.14-16
Study definitions
	We analyzed all patients who underwent PCI in England and Wales between 1 January 2007 and 31 December 2014 on the BCIS database.  We then classified participants as (i) patients with in-hospital retroperitoneal hemorrhage and (ii) patients without in-hospital retroperitoneal hemorrhage.  The outcomes of interest were 30-day and 1-year mortality and in-hospital MACE.  MACE was defined by the composite of in-hospital death, myocardial infarction or re-infarction.
	Additional data were collected on patient demographics, comorbidities and treatments received.
Statistical analysis
Statistical analyses were performed on Stata/MP version 14.0 (Stata Corp, College Station, Texas, USA). Descriptive statistics were presented in tables by in-hospital retroperitoneal hemorrhage status and access site (non-femoral access and femoral access).  The in-hospital retroperitoneal hemorrhage rates over time were explored graphically. Kaplan-Meier curves were plotted for 30 days and 1-year mortality by retroperitoneal hemorrhage status. Multiple imputations with chained equations were used to account for missing data. All outcomes were included in the imputation model, but not imputed.17 The extent of data missingness is shown in Supplementary Table 1.  Multiple logistic regressions were performed to identify predictors of in-hospital retroperitoneal hemorrhage. Further subgroup analyses were performed to evaluate patients who received any transfusion (blood transfusion or platelet transfusion) and no transfusion and those who had surgical intervention and those without surgical intervention, amongst cases with retroperitoneal hemorrhage.






	The analysis included a total of 291 retroperitoneal hemorrhage events that occurred in 511,106 participants.  Supplementary Figure 1 shows the process of participant inclusion.  The extent of missing data for the participants is shown in Supplementary Table 1.
	Rates of retroperitoneal hemorrhage declined over time from 0.09% to 0.03% between 2007 to 2014 (Figure 1A).  The results of the trend analysis suggest that there is a significant trend (p<0.001). During the same time-period, radial access in this cohort grew from 24% to 71% (Figure 1B). The temporal rates of retroperitoneal hemorrhage over time for different subgroups of participants are shown in Figure 2 and Supplementary Table 2.  The greatest decline was observed for patients who were aged 80 or older, were female and had a diagnosis of STEMI.  Rates of retroperitoneal hemorrhage among cases undertaken through the femoral access site have not significantly changed over time. 
	The baseline characteristics according to retroperitoneal hemorrhage are shown in Table 1.  Participants with retroperitoneal hemorrhage were more likely to be female (p<0.001) and diabetic (p=0.03) and more likely have femoral access (p<0.001) and receive circulatory support (p<0.001).  Glycoprotein IIb/IIIa inhibitor (p<0.001) and clopidogrel (p=0.001) were more often used in patients with retroperitoneal hemorrhage and they were less likely to receive ticagrelor (p=0.001). Both outcomes 30-day mortality and in-hospital MACE were greater in the retroperitoneal hemorrhage group (8% vs 2% and 9% vs 2%, respectively) and patients with retroperitoneal hemorrhage were more likely to have blood transfusion, platelet transfusion or vascular surgery (47% vs 0.2%, 8% vs 0.03%, 7% vs 0.03%, respectively). 
	The vast majority of retroperitoneal bleeds occurred in patients who underwent PCI through the TFA approach (266/279; 95.3%) although a small number of retroperitoneal bleeding events occurred in patients who underwent PCI through the TRA approach (12/279; 4.7%). The baseline characteristics tables according to non-femoral and femoral access site for the PCI and retroperitoneal bleed status are shown in Supplementary Table 3 and 4.  Patients with non-femoral access were more likely to have retroperitoneal bleed if they were female (p=0.010) and had valvular heart disease (p<0.001), cardiogenic shock (p=0.039), received circulatory support (although this represented only 1 out of the 13 “non-femoral” cases; p<0.001) and warfarin therapy (p=0.02).  In terms of crude outcomes, in-hospital MACE (p<0.001), blood transfusion (p<0.001) and hemorrhage or access site complication requiring surgery (p<0.001) was higher in the retroperitoneal hemorrhage group.  Patients with femoral access were more likely to have retroperitoneal bleed if they were female (p<0.001), had lower body mass index (p=0.004), did not have diabetes (p=0.009), received circulatory support (p=0.02), had a STEMI diagnosis (p=0.04), received glycoprotein IIb/IIIa inhibitor use (p<0.0010), or received prasugrel (p=0.030).  30-day mortality, in-hospital MACE, blood transfusion, platelet transfusion and hemorrhage or access site complication requiring surgery were all higher in the retroperitoneal bleed group (p<0.001).
	The predictors of retroperitoneal hemorrhage are shown in Table 2.  The strongest independent predictor for retroperitoneal hemorrhage was femoral access, with an odds ratio (OR) of 19.66 (95% CI: 11.22, 34.43). Other predictors associated with retroperitoneal hemorrhage for the cases undertaken only though the femoral approach or in cases where non-femoral access sites were utilized include female sex (OR=5.29 95% CI: 4.13, 6.78), hypercholesterolemia (OR=1.37 95% CI: 1.05, 1.78), circulatory support (OR=2.26 95% CI: 1.21, 4.23), glycoprotein IIb/IIIa inhibitor use (OR=2.63 95% CI: 1.99, 3.47) and warfarin (OR=2.53 95% CI: 1.07, 5.99).  When access site was considered, femoral access patients were less likely to be diabetic (OR=0.67 95% CI: 0.47, 0.96) and for non-femoral access site, patients with hemorrhage events were more likely to have valvular heart disease (OR 8.58 95% CI: 1.65, 44.52).
	In terms of management, patients with retroperitoneal bleed were more likely to have blood transfusion (46% vs 0.09%, p<0.001) and surgery (15% vs 0.02%, p<0.001) compared to those without bleeds and the rates of adverse outcomes according to management is shown in Table 3.  Patients treated with surgical intervention who did not receive a blood transfusion had the highest mortality and in-hospital MACE. Outcomes in relation to access site and management are shown in Supplementary Table 5.  For patients with femoral access, those who received surgery had the greatest mortality rates at 30 days (11%).  Supplementary Table 6 shows the length of stay for the entire cohort and in subgroups of patients.
	The Kaplan Meier survival curve for 30 day mortality and 1 year mortality according to retroperitoneal hemorrhage is shown in Figure 3.  Mortality was greater in the hemorrhage group at all time points and survival curves were significant by log-rank test (p<0.001).





	We are the first to report national trends in retroperitoneal hemorrhage, clinical characteristics and outcomes of patients following PCI. Our analysis of a national PCI cohort has demonstrated that the incidence of retroperitoneal hemorrhage has decreased over time in a country that has predominantly transitioned to transradial access for PCI and that 95% of retroperitoneal hemorrhage occurred in patients who underwent PCI through the femoral approach (which independently increased the odds of sustaining a retroperitoneal hemorrhage over 20-fold). The reduction in retroperitoneal hemorrhage was mainly observed in elderly patients (>80 years old), females and those with STEMI presentation. We also observe that retroperitoneal bleeds can occur when radial access is used, albeit much more rarely (<0.005%). Retroperitoneal hemorrhage is independently associated with a 3-fold increase in mortality and a 5-fold increase in adverse cardiovascular outcomes, although we observe no legacy effect for patients who survive to 30 days.
	Retroperitoneal hemorrhages tend to be associated with high femoral artery punctures.19 This is because punctures and sheath insertion above the inguinal ligament into the external iliac artery may predispose uncontrolled bleeding due to the difficulty in achieving compression of this vessel.20 However low femoral artery punctures do not eliminate the risk of retroperitoneal bleed.  The insertion of the sheath in the common femoral artery well below the inguinal ligament can still lead to spread of bleeding from the puncture site along well-defined anatomic fascial planes to cause bleeding into the retroperitoneum.19   Studies have suggested that the retroperitoneal space appears to be able to sequester large amount of blood and an external fluid compression to occlude the leak will occur in virtually all patients if blood volume is replaced.7,10  Therefore management involves volume and blood product support and correction of thrombin and platelet inhibition.7 CT is useful in identifying the source and extent of bleeding, and guiding surgery that may be needed for uncontrolled bleeding, clinically significant organ damage or nerve compression.7
	Several studies have reported factors associated with retroperitoneal hemorrhage.  Our finding that older patients are more likely to have retroperitoneal hemorrhage is supported by a study where majority of patients with spontaneous retroperitoneal hematomas occurred in elderly patients.21,22 Furthermore, the elderly are more likely to have access site related complications and associated bleeding events.23 Female sex was a common predictor of retroperitoneal hemorrhage in multiple studies.5,7,10  Women may be more likely to have retroperitoneal hemorrhage post PCI as they are more comorbid24 and have local anatomical differences in access site such as a shorter common femoral artery,15 smaller vessel diameter15,25 and a reduced area for safe vascular puncture.15 Glycoprotein IIb/IIIa inhibitors are powerful antithrombotic drugs which have been observed in our study and other studies5,7 to predict retroperitoneal hemorrhage. 
	One novel finding was that patients with retroperitoneal bleed were more likely to have hypercholesterolemia.  While it is not entirely clear, one explanation may be that hypercholesterolemia or statin use may be a surrogate for diseased or calcified vessels with heavy atherosclerotic burden which may be more likely to bleed.
The present analysis reported lower rates of retroperitoneal bleed compared to existing studies (Supplementary Table 7). Firstly, over half of our cohort was a radial cohort whereas previous literature was derived from studies performed almost exclusively through the femoral approach that would contribute to greater reported RP bleeding rates in previous analyses.4,7,19,26,27 Secondly our study was undertaken in a more contemporary era and pharmacological practice reflects this with only 20% of cases receiving GPIIb/IIIa inhibition compared to studies where rates can be as high as 44%.26 Finally several of the previous studies7,26 were derived from cohorts in the 1990’s where larger bore guide catheters were more commonly used and ultrasound guided puncture that has been shown to be associated with less access site complications was less common practice.
	A few studies have previously reported similar adverse outcomes associated with retroperitoneal hemorrhage following PCI that we have observed (Supplementary Table 8 and 9).  In our current study, we report crude 30-day mortality rates of 8% vs 2% and in-hospital MACE of 9% vs 2%, which after adjustment is associated with 3-fold odds of 30-day mortality and 5-fold odds of in-hospital MACE.  The only large multicenter registry to date from the North America reported similar outcomes, although did not examine mortality outcomes or temporal trends in rates of retroperitoneal hemorrhage.4 
	We were also able to consider the association of different therapies and outcomes following retroperitoneal hemorrhage, which has not been reported in previous studies.  In our cohort, 47% of patients with retroperitoneal hemorrhage receive blood transfusion and 7% require surgical intervention. Worse outcomes were associated with surgery and this may reflect ongoing or more severe hemorrhage with significant hemodynamic compromise that does not respond to conservative management hence the need to intervene and worse outcomes. 
	Other studies have reported an association between bleeding and mortality at one year but have not specifically looked for the presence of a legacy effect, which we have shown does not exist.  The term 'legacy effect' is used to describe the residual risk of later mortality in patients who survive the acute event.  This has been observed in patients with coronary perforation complicating PCI.18 
	Several mechanisms have been described that link retroperitoneal hemorrhage to mortality and thrombotic complications.1  Increased mortality may relate to the bleeding event itself or to the discontinuation of antithrombotic agents.28,29  In addition, there is a natural hemostatic response to local bleeding and this response may systemically amplify leading to stent thrombosis.30 Anemia secondary to bleeding might also stimulate prothrombotic factors such as erythropoietin and plasminogen activator inhibitor-1 and lead to stent thrombosis.31,32 
	We have also investigated temporal trends in retroperitoneal hemorrhage nationally and show that this complication has declined over time.  Several other concomitant temporal changes occurred during this study including the decline in the use of thrombolysis and the rise of more powerful antiplatelet such as ticagrelor, prasugrel and glycoprotein IIb/IIIa inhibitors that contributed to the changes that we have reported. While these other changes are likely to have associations with the changes in RP bleeding rates, it is likely that the largest contributor to this decline was the national switch to radial access as the predominant access site for PCI.  Another possible contributor to the decline in hemorrhage is that operators are adopting more optimal access site strategies to avoid retroperitoneal bleeds when femoral access site is chosen such as ultrasound-guided femoral artery access and use of micropuncture techniques with a 21-gauge micropuncture needle enabling puncture of the safe zone of the femoral artery33 that have been shown to reduce access site complications.34
	The high proportion of patients with non-femoral access procedures in our cohort provides insight into spontaneous retroperitoneal hemorrhage. Rates of bleeding are substantial lower than those reported in patients with femoral access (only 13 bleeds over 8 year period in 256,953 patients; <0.005%) with only female sex and prevalent valvular heart disease were independently associated with these bleeds. The prevalence of valvular heart disease may act as a surrogate for anti-coagulation use and a previous case series has reported such spontaneous retroperitoneal bleeding events among patients treated with anticoagulation, bleeding abnormalities and hemodialysis35 whilst another case report has reported it in association with clopidogrel therapy.36  The exact mechanism of spontaneous retroperitoneal hemorrhage is unknown but it has been suggested that diffuse occult vasculopathy and arteriosclerosis of the small vessels in the retroperitoneum may render them more friable and prone to rupture or bleeding may occur at microvascular level and large vessels become disrupted and stretched as hematoma enlarges.37  	 
	There are no randomized trials to guide the treatment strategies for retroperitoneal hemorrhage and for most patients, management involves close monitoring, vigorous fluid resuscitation, blood transfusion and reversal of anticoagulation.20 If patients remain unstable despite aggressive resuscitation with uncontrolled bleeding, a percutaneous strategy with embolization, coil deployment, gelatin and polyvinyl alcohol38 is preferred over open surgery.20
	Our study has several strengths. We present the first study of a national PCI cohort where there has been a change in access site practice.  Unlike previous studies we could evaluate a long period of time and this enabled evaluation of temporal changes in practice and outcomes.  We were also able to consider many clinical variables, procedural factors and management factors including antithrombotic medications, blood transfusion and receipt of surgery and their association with development of retroperitoneal bleeding and how they affect subsequent adverse outcomes. 
	Our study has several limitations. First the observational nature of the study methodology means the findings could be at risk of confounding.  To limit this effect, we attempted to adjust for the effect of several variables.  Secondly, because the study is observational we cannot determine causality in the associations observed.  Bleeding complications may also be underreported in the BCIS dataset especially small bleeds, as these are self-reported events and not externally validated.  Several studies of retroperitoneal bleed have highlighted the use of imaging such as ultrasound6 or CT scan although the BCIS dataset does not capture these investigations.1 Also, our study is limited because we do not have information on the timing of in-hospital mortality events and exsanguination or severity of the blood loss. Another limitation is that there is no external validation of the data collected. However, there are processes that check the range of values of collected variables and other checks for internal consistency.  Corrected data is requested for any errors identified and these errors are directly fed back to the center where the procedure was performed.  Furthermore, the data performance is publicly reported, both at operator and PCI centre level (see www.BCIS.org.uk/patient-area (​http:​/​​/​www.bcis.org.uk​/​patient-area" \t "_blank​)) and prior to publication of the report there are 2 rounds of data validation. A further limitation was that we were not able to look at possible clustering effects associated by sites because there were too few retroperitoneal bleeding events (n=291) relative to the PCI sites in the study (n=92). Finally, it is known that the severity of bleeds is associated with future prognosis,39 but the BCIS dataset does not capture information relating to either the severity of bleeds, investigations of the bleeds or changes in antithrombotic therapy in response to the bleeding event. The dataset simply collects information about the receipt of a blood transfusion or the use of surgical intervention.
	In conclusion, we have shown that the rate of retroperitoneal hemorrhage following PCI has declined in England and Wales from 2007 to 2014.  This decline is most marked among patients aged 80 year or greater, female patients and patients with a diagnosis of STEMI.  We demonstrate that femoral access is independently associated with 20-fold odds of retroperitoneal hemorrhage compared to non-femoral access.  Mortality and in-hospital MACE are significantly higher in patients who develop retroperitoneal hemorrhage, but patients who survive the acute event do not have increased risk of later mortality.
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 Table 1: Characteristics of participants
Variable	No RP bleed (n=511,106)	RP bleed (n=291)	p-value
Age	65±12	66±13	0.10
Female sex	131,056 (26%)	188 (65%)	<0.001
Body mass index	28±5	27±5	<0.001
Current smoker	110,608 (24%)	65 (25%)	0.84
Diabetes 	96,897 (20%)	41 (15%)	0.03
Hypertension	269,761 (55%)	153 (54%)	0.79
Hypercholesterolemia	277,400 (57%)	174 (62%)	0.09
Previous MI	129,353 (28%)	75 (27%)	0.71
Previous stroke	19,610 (4%)	12 (4%)	0.84
Peripheral vascular disease	23,655 (5%)	14 (5%)	0.92
Renal disease	5,850 (1%)	4 (1%)	0.74
Valvular heart disease	6,592 (1%)	6 (2%)	0.26
Previous PCI	113,680 (23%)	64 (23%)	0.92
Previous CABG	42,238 (9%)	26 (9%)	0.70
Femoral access	244,639 (49%)	266 (96%)	<0.001
Cardiogenic shock	11,258 (2%)	9 (3%)	0.25
Circulatory support	8,108 (2%)	14 (5%)	<0.001
Receipt of ventilation	7,100 (2%)	2 (1%)	0.28
DiagnosisStable anginaNSTEMI/UASTEMI	182,051 (37%)190,682 (39%)113,383 (23%)	95 (34%)114 (41%)69 (25%)	0.53







Year20072008200920102011201220132014	46,925 (9%)55,449 (11%)60,680 (12%)63,475 (12%)67760 (13%)71,715 (14%)71,613 (14%)73,198 (14%)	42 (14%)43 (15%)44 (15%)42 (14%)31 (11%)30 (10%)36 (12%)23 (8%)	<0.001
30-day mortality	11,247 (2%)	23 (8%)	<0.001
In-hospital MACE	8,200 (2%)	27 (9%)	<0.001
Blood transfusion	961 (0.2%)	135 (47%)	<0.001
Platelet transfusion	161 (0.03%)	22 (8%)	<0.001
Hemorrhage or access site complication requiring surgery	176 (0.03%)	21 (7%)	<0.001
Table 2: Multivariable predictors of RP bleed
Full cohort
Variable	Odds ratio (95% CI)	p-value
Female sex	5.29 (4.13-6.78)	<0.001




Glycoprotein IIb/IIIa inhibitor	2.63 (1.99-3.47)	<0.001
Warfarin	2.53 (1.07-5.99)	0.035
Femoral access
Variable	Odds ratio (95% CI)	p-value
Female sex	5.38 (4.16-6.94)	<0.001




Glycoprotein IIb/IIIa inhibitor	2.59 (1.94-3.45)	<0.001
Non-femoral access
Variable	Odds ratio (95% CI)	p-value
Female sex	3.95 (1.30-12.04)	0.016
Valvular heart disease	8.58 (1.65-44.52)	0.011
Glycoprotein IIb/IIIa inhibitor	3.93 (1.05-14.76)	0.042
*All variables in Table 1 except for ticlopidine, 30-day mortality, in-hospital MACE, blood transfusion and platelet transfusion.  Renal disease for all models and coronary artery bypass graft for model C was not included in adjustment because the model did not converge.


Table 3: Outcomes in relation to management
Outcome or subgroup	Without adverse outcome	With adverse outcomes
30-day mortalityNo RP bleedRP bleed and no transfusionRP bleed and transfusionRP bleed and surgical interventionRP bleed and no surgical intervention	499,568 (98%)141 (91%)127 (94%)19 (90%)246 (92%)	11,247 (2%)14 (9%)8 (6%)2 (10%)21 (8%)
In-hospital MACENo RP bleedRP bleed and no transfusionRP bleed and transfusionRP bleed and surgical interventionRP bleed and no surgical intervention	502,615 (98%)139 (90%)125 (93%)19 (90%)244 (91%)	8,200 (2%)16 (10%)10 (7%)2 (10%)23 (9%)


Table 4: Multivariable risk of adverse outcome with RP bleed
Group	Adverse outcome	n	Odds ratio (95% CI)	p-value
Whole cohort	30 day mortality	511,106	3.59 (2.19-5.90)	<0.001
	In-hospital MACE	511,106	5.76 (3.71-8.95)	<0.001
Receipt of transfusion	30 day mortality	510,950	2.41 (1.08-5.41)	0.032
	In-hospital MACE	510,950	4.14 (2.04-8.40)	<0.001
No transfusion	30 day mortality	510,970	4.38 (2.30-8.36)	<0.001
	In-hospital MACE	510,970	6.85 (3.85-12.21)	<0.001
Surgical intervention	30 day mortality	510,836	8.94 (2.00-40.06)	0.004
	In-hospital MACE	510,836	9.06 (2.06-39.82)	0.004
No surgical intervention	30 day mortality	511,082	3.56 (2.14-5.94)	<0.001
	In-hospital MACE	511,082	5.25 (3.28-8.41)	<0.001





Figure 1: Rates of RP bleed over time and growth of radial access





Figure 3: Kaplan-Meier survival curves at 30 days and 1 year 

Data Supplements 1
The British Cardiovascular Intervention Society database
The British Cardiovascular Intervention Society (BCIS) routinely collects data on all PCI procedures in the United Kingdom.  The National Institute of Cardiovascular Outcomes Research (NICOR) oversees the collection of the data.  In 2011, this database collected information on 99% of all PCI procedures performed in National Health Service Hospitals in England and Wales.14-16
	The BCIS-NICOR database contains 113 variables that includes clinical variables, procedural parameters and patient outcomes.  Mortality information is obtained from the Office of National Statistics using linkage with the patient’s unique National Health Service number for patients from England and Wales.  Participants from Scotland or Northern Ireland were not included in the study because mortality tracking was not available.  
	Ethical approval was not required as only anonymized routinely collected data were used.
Study definitions
	We analyzed all patients who underwent PCI in England and Wales between 1 January 2007 and 31 December 2014 on the BCIS database.  Patients were excluded if their records did not contain mortality information, in-hospital major adverse cardiovascular events (MACE) and retroperitoneal hemorrhage.  We then classified participants as (i) patients with in-hospital retroperitoneal hemorrhage and (ii) patients without in-hospital retroperitoneal hemorrhage.  The outcomes of interest were 30-day and 1-year mortality and in-hospital MACE.  MACE was defined by the composite of in-hospital death, myocardial infarction or re-infarction.
Data collection
Additional data were collected on participant age, sex, body mass index, current smoking status, diabetes mellitus, hypertension, hypercholesterolemia, previous myocardial infarction, previous stroke, peripheral vascular disease, renal disease, valvular heart disease, previous PCI, previous CABG, use of radial access, cardiogenic shock, use of circulatory support, receipt of ventilation, diagnosis (stable angina, NSTEMI/unstable angina, STEMI), use of glycoprotein IIb/IIIa inhibitor, antiplatelet use (clopidogrel, prasugrel, ticagrelor, ticlopidine), warfarin use, thrombolysis, year of PCI and receipt of in-hospital blood transfusion.
Statistical Analysis
Descriptive statistics were presented in tables by in-hospital retroperitoneal hemorrhage status and access site (non-femoral access and femoral access).  The in-hospital retroperitoneal hemorrhage rates over time were explored graphically in the entire cohort and presented by subgroups based on age (<60 years, 60-80 years, >80 years), sex, diagnosis (stable angina, NSTEMI/unstable angina and STEMI) and access site (non-femoral access and femoral access). Continuous variables were presented using means and standard deviations, while the difference between the two groups was determined with ANOVA tests.  Categorical variables were presented as frequencies and percentages, while chi-squared tests were used to determine group differences. Kaplan-Meier curves were plotted for 30 days and 1 year mortality, by retroperitoneal hemorrhage status, to provide an unadjusted overview or relative survival.
Multiple imputations with chained equations were used to account for missing data.  Using the mi impute chained function in Stata we generated 10 complete datasets with imputed data for missing data. All outcomes were included in the imputation model, but not imputed.17 The extent of data missingness is shown in Supplementary Table 1.  
Using the imputed dataset, multiple logistic regressions were performed to identify predictors of in-hospital retroperitoneal hemorrhage. We did not use a survival analysis model since follow-up information was complete for all patients and no censorship occurred.  All variables except blood transfusion, outcomes and variables which caused failure of convergence of models were included in this model.  Ticlopidine was not included in this model because very few patients received this treatment and no hemorrhage events occurred in this small group.  Next, univariable and multivariable logistic regressions were used to quantify the association of in-hospital retroperitoneal hemorrhage with 30-day mortality and in-hospital MACE.  All variables were included in the multivariable models except for variables which caused the models not to converge.  Further subgroup analyses were performed to evaluate patients who received any transfusion (blood transfusion or platelet transfusion) and no transfusion and those who had surgical intervention and those without surgical intervention, amongst cases with retroperitoneal hemorrhage.




Supplementary Figure 1: Flow diagram - England and Wales only, exclude missing RP bleed and mortality












































Supplementary Table 2: Rates of bleeding over time
Group	2007	2008	2009	2010	2011	2012	2013	2014
Overall	42 (0.09%)	43 (0.08%)	44 (0.07%)	42 (0.07%)	31 (0.05%)	30 (0.04%)	36 (0.05%)	23 (0.03%)
Age <60	13 (0.08%)	16 (0.08%)	14 (0.07%)	15 (0.07%)	12 (0.05%)	7 (0.03%)	10 (0.04%)	4 (0.02%)
Age 60-80	23 (0.08%)	22 (0.07%)	26 (0.07%)	22 (0.06%)	17 (0.04%)	17 (0.04%)	24 (0.06%)	15 (0.04%)
Age >80	6 (0.20%)	5 (0.13%)	4 (0.08%)	5 (0.09%)	2 (0.03%)	6 (0.08%)	2 (0.03%)	4 (0.05%)
Women	30 (0.25%)	28 (0.20%)	33 (0.21%)	23 (0.14%)	19 (0.11%)	19 (0.10%)	21 (0.11%)	15 (0.08%)
Men	12 (0.03%)	15 (0.04%)	11 (0.02%)	19 (0.04%)	12 (0.02%)	11 (0.02%)	15 (0.03%)	8 (0.01%)
Stable angina	14 (0.07%)	15 (0.06%)	12 (0.05%)	10 (0.04%)	14 (0.06%)	11 (0.05%)	13 (0.06%)	6 (0.03%)
NSTEMI/UA	19 (0.10%)	14 (0.07%)	20 (0.09%)	15 (0.06%)	9 (0.04%)	13 (0.05%)	13 (0.05%)	11 (0.04%)
STEMI	8 (0.15%)	11 (0.14%)	11 (0.10%)	12 (0.08%)	8 (0.05%)	6 (0.03%)	9 (0.05%)	4 (0.02%)
Femoral access	40 (0.12%)	39 (0.10%)	41 (0.11%)	36 (0.11%)	28 (0.09%)	27 (0.10%)	33 (0.14%)	22 (0.10%)




Supplementary Table 3: Characteristics of participants by retroperitoneal bleed with non-femoral access
Variable	No retroperitoneal bleed (n=256,940)	Retroperitoneal bleed (n=13)	p-value
Age	64±12	66±11	0.49
Female sex	60,488 (24%)	7 (54%)	0.01
Body mass index	29±5	25±3	0.05
Current smoker	61,303 (26%)	2 (15%)	0.39
Diabetes 	47,329 (19%)	4 (31%)	0.28
Hypertension	135,841 (55%)	7 (54%)	0.94
Hypercholesterolemia	139,339 (56%)	9 (69%)	0.35
Previous MI	59,356 (25%)	3 (23%)	0.91
Previous stroke	9,948 (4%)	0 (0%)	0.46
Peripheral vascular disease	11,880 (5%)	1 (8%)	0.63
Renal disease	4,995 (2%)	1 (8%)	0.15
Valvular heart disease	3,255 (1%)	2 (15%)	<0.001
Previous PCI	52,493 (21%)	3 (23%)	0.84
Previous CABG	12,085 (5%)	0 (0%)	0.42
Cardiogenic shock	3,126 (1%)	1 (8%)	0.039
Circulatory support	1,641 (0.7%)	1 (10%)	<0.001
Receipt of ventilation	2,128 (0.9%)	0 (0%)	0.73
DiagnosisStable anginaNSTEMI/UASTEMI	82,886 (34%)101,164 (41%)62,595 (25%)	5 (38%)6 (46%)2 (15%)	0.71







Year20072008200920102011201220132014	11,074 (4%)16,286 (6%)23,085 (9%)29,165 (11%)36,183 (14%)42,741 (17%)47,125 (18%)51,281 (20%)	1 (8%)2 (15%)1 (8%)3 (23%)2 (15%)3 (23%)0 (0%)1 (8%)	0.40
30-day mortality	3,796 (1%)	0 (0%)	0.66
In-hospital MACE	2,765 (1%)	2 (15%)	<0.001
Blood transfusion	236 (0.09%)	6 (46%)	<0.001
Platelet transfusion	45 (0.02%)	0 (0%)	0.96
Haemorrhage or access site complication requiring surgery	40 (0.02%)	2 (15%)	<0.001

Supplementary Table 4: Characteristics of participants by retroperitoneal bleed with femoral access
Variable	No retroperitoneal bleed (n=244,639)	Retroperitoneal bleed (n=266)	p-value
Age	64±12	66±11	0.75
Female sex	68,088 (28%)	175 (65%)	<0.001
Body mass index	28±5	27±5	0.004
Current smoker	47,594 (22%)	62 (26%)	0.22
Diabetes 	47,986 (21%)	36 (14%)	0.009
Hypertension	130,785 (56%)	139 (54%)	0.57
Hypercholesterolemia	134,958 (58%)	159 (62%)	0.17
Previous MI	67,703 (31%)	71 (28%)	0.22
Previous stroke	9,358 (4%)	12 (5%)	0.59
Peripheral vascular disease	11,375 (5%)	812 (5%)	0.88
Renal disease	8,273 (4%)	8 (3%)	0.68
Valvular heart disease	3,260 (1%)	4 (2%)	0.83
Previous PCI	59,286 (25%)	58 (22%)	0.30
Previous CABG	29,376 (13%)	24 (9%)	0.12
Cardiogenic shock	7,927 (3%)	8 (3%)	0.89
Circulatory support	6,339 (3%)	13 (5%)	0.02
Receipt of ventilation	4,853 (2%)	2 (0.8%)	0.12
DiagnosisStable anginaNSTEMI/UASTEMI	95,139 (41%)86,334 (37%)49,207 (21%)	85 (34%)104 (41%)64 (25%)	0.04







Year20072008200920102011201220132014	34,626 (14%)37,244 (15%)36,563 (15%)33,180 (14%)30,526 (12%)28,029 (11%)23,402 (10%)21,069 (9%)	40 (15%)39 (15%)41 (15%)36 (14%)28 (11%)27 (10%)33 (12%)22 (8%)	0.81
30-day mortality	7,223 (3%)	23 (9%)	<0.001
In-hospital MACE	5,279 (2%)	25 (9%)	<0.001
Blood transfusion	709 (0.3%)	124 (47%)	<0.001
Platelet transfusion	114 (0.05%)	21 (8%)	<0.001




Supplementary Table 5: Outcomes in relation to management by access site
Outcome or subgroup	Without adverse outcome	With adverse outcomes
Non-femoral access 30-day mortalityNo RP bleedRP bleed and no transfusionRP bleed and transfusionRP bleed and surgical interventionRP bleed and no surgical intervention	253,144 (99%)7 (100%)6 (100%)2 (100%)11 (100%)	3,796 (1%)0 (0%)0 (0%)0 (0%)0 (0%)
Femoral access 30-day mortalityNo RP bleedRP bleed and no transfusionRP bleed and transfusionRP bleed and surgical interventionRP bleed and no surgical intervention	237,416 (97%)127 (90%)116 (94%)16 (89%)224 (91%)	7,223 (3%)14 (10%)8 (6%)2 (11%)21 (9%)
Non-femoral access in-hospital MACENo RP bleedRP bleed and no transfusionRP bleed and transfusionRP bleed and surgical interventionRP bleed and no surgical intervention	254,175 (98%)5 (71%)6 (100%)2 (100%)9 (82%)	2,765 (1%)2 (29%)0 (0%)0 (0%)2 (18%)





Supplementary Table 6: Characteristics of participants and rates of retroperitoneal hemorrhage in previous meta-analysis and current study

Study ID	Date of study	Mean age	Glycoprotein IIb/IIIa inhibitor use	Radial access	STEMI patients	% RP bleed
Doyle 2008	1994 to 2005	65.5 years	44.1%	0%	16.2% MI <24h prior.	0.4%
Ellis 2006	1992 to 2003	64.0 years	40.4%	0% virtually all patients had vascular access via femoral artery.	-	0.6%
Farouque 2005	2000 to 2004	66.7 years	69% in cases and 61% in controls	0%	8% in cases and 18% in controls.	0.7%
Ndrepepa 2013	2000 to 2011	67.4 years (full cohort)	25%	0% virtually all femoral access in all but 6 patients.	STEMI excluded.	0.2%
Trimarchi 2010	2002 to 2007	64.0 years	11.0%	Likely all femoral access.	Acute MI <24 h 17.0%	0.4%




Supplementary Table 7: List of studies reporting retroperitoneal hemorrhage post coronary procedure
Study ID	Country	Year	Sites	Cohort type	No. RP bleed	No. Total	% RP bleed	% death with RP bleed	% death with no RP bleed
Crudu 2011	USA	2005 - 2008	Single center	PCI cohort	25 bleeds	3940 PCI procedures	0.63%	4.7% with vascular complication	1.1% no vascular complication
Dencker 2016	Denmark	2006 - 2012	Two centers	Angiography and PCI cohort	6 hematomas	23,870 procedures	0.025%	4.6% with vascular complication at 30 days	3.1% no vascular complication at 30 days
Doyle 2008	USA	1994-2005	Single center	PCI cohort	65 retroperitoneal bleeds	17,901 procedures	0.36%	-	-
Ellis 2006	USA	1992 - 2003	Single center	PCI cohort	164 bleeds	28,378 PCI procedures	0.58%	10%	0.7%
Exaire 2004	International	1999 - 2000	Multicenter	Non-emergent PCI cohort	29 bleeds	3,732 PCI procedures	0.61%	-	-
Farouque 2005	USA	2000-2004	Single	PCI cohort	26 bleeds	3,508 patients	0.74%	-	-
Kent 1994	USA	1988 - 1993	Single center	Femoral catheterization cohort	45 bleeds	9,585 procedures	0.47%	2.2% (1/45)	-
Maluenda 2012	USA	2000 - 2009	Single center	PCI cohort	93 bleeds	20,904 PCI procedures	0.43%	7.5%	-
Mehta 2009	USA	2004 - 2006	Multicenter 440 hospitals	PCI cohort	941 bleeds	302,152 PCI procedures	0.31%	-	-
Ndrepepa 2013	International	2000-2011	Multicenter	PCI trials	26 bleeds	14,180 PCI procedures	0.46%	3.8% at 1 year.	2.4% at 1 year.
Romaguera 2012	USA	2003 - 2009	Single center	PCI cohort	51 bleeds	7,718 PCI procedures	0.66%	-	-
Tremmel 2012	USA	2006	Single center	PCI cohort	5 bleeds	557	0.9%	-	-
Trimarchi 2010	USA	2002 - 2007	Multicenter	PCI cohort	482 hematoma	112,340 PCI procedures	0.4%	6.6%	1.1%










Ellis 2006	Multivariate: Sheath superior to inferior epigastric artery, female sex, angioseal, glycoprotein IIb/IIIa inhibitor use, acute myocardial infarction and low body weight.
Exaire 2004	-
Farouque 2005	Multivariate: Female sex, reduced body surface area and high femoral puncture.
















Final sample size is n=511,106 with  291 RP bleeds.

Total cohort in England and Wales n=593,058.



